Abstract:Background: Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer death worldwide and compared to other malignancies its share in cancer mortality is expected to rise further. This is due to a lack of sensitive diagnostic tools that would permit earlier detection in a potentially curable stage and the very slow progress in finding effective drug treatments for pancreatic cancer. Key Messages: Aside from genetic predispositions and environmental agents, chronic pancreatitis is by far the greatest risk factor for PDAC. It also shares several etiological factors with pancreatic cancer and represents its most challenging differential diagnosis. Biomarkers that can distinguish between chronic pancreatitis and PDAC may therefore be suitable for the latter's early detection. Moreover, targeting the natural history of chronic pancreatitis would be one approach to prevent PDAC. Targeting tumor-cell signaling directly by interfering with receptor tyrosine kinases has shown some efficacy, although the results in clinical trials were less encouraging than for other cancers. Other compounds developed have targeted the formation of extracellular matrix around the tumor, the proteolytic activity in the tumor environment, histone deacetylases, hedgehog signaling and heat shock proteins, but none has yet found its way into routine patient care. Attempts to individualize treatment according to the tumor's somatic mutation profile are novel but so far impractical. Conclusions: Progress in the treatment of pancreatic cancer has been exceedingly slow and mostly dependent on improved pharmaceutical preparations or combinations of established chemotherapeutic agents. The promise of major breakthroughs implied in targeting tumor signal transduction events has so far not materialized.

Emerging horizons on molecular and circulating biomarkers in pancreatic adenocarcinoma

Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians

Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma

Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies–From Discovery to Knowledge-Guided Platforms for Better Patient Management

Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting

The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy

Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma

Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer

Emerging pathways and future targets for the molecular therapy of pancreatic cancer

Advances in Pancreatic Cancer Research: Moving Towards Early Detection.

Therapeutic developments in pancreatic cancer

The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma

Emerging Horizons in the Diagnosis of Pancreatic Cancer: The Role of Circulating microRNAs as Early Detection Biomarkers for Pancreatic Ductal Adenocarcinoma

Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy—A Review of the Literature

Development of Pancreatic Cancer: Targets for Early Detection and Treatment

Molecular pathology and protein markers for pancreatic cancer: relevance in staging, in adjuvant therapy, in determination of minimal residual disease, and follow-up

The Past, Present, and Future of Biomarkers for the Early Diagnosis of Pancreatic Cancer

Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers' Discovery

Early diagnosis of pancreatic cancer: What strategies to avoid a foretold catastrophe

Circulating Biomarkers for Early Diagnosis of Pancreatic Cancer: Facts and Hopes.

Biomarkers for early detection of pancreatic cancer – miRNAs as a potential diagnostic and therapeutic tool?